04 Jun, 13:24 - Indian

SENSEX 80945.33 (0.26)

Nifty 50 24602.35 (0.24)

Nifty Bank 55627.2 (0.05)

Nifty IT 36999.9 (0.50)

Nifty Midcap 100 57735.8 (0.38)

Nifty Next 50 66730.1 (0.09)

Nifty Pharma 21359.2 (0.02)

Nifty Smallcap 100 18218.5 (0.58)

04 Jun, 13:24 - Global

NIKKEI 225 37747.45 (0.80)

HANG SENG 23654.04 (0.60)

S&P 6000.25 (0.11)


Corporate News

You are Here : Home > News > Corporate News >

(12 Mar 2025, 13:29)

Glenmark Pharmaceuticals launches Empagliflozin in India

Used to improve glycemic control in adults with cardiovascular disease


Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. 

Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.


More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +